Oxybutynin (low-dose extended release)
Treatment for Menopause
Typical Dosage: 2.5-5mg extended-release orally once daily
Effectiveness
60%
Safety Score
55%
Clinical Trials
8
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
2.5-5mg extended-release orally once daily
Time to Effect
2-4 weeks
Treatment Duration
Long-term, as needed
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
500(Treat 500 patients to see 1 additional serious adverse event)
Confidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$330
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$660
Cost per Remission
$1,650
Oxybutynin (low-dose extended release) Outcomes
for Menopause
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+50%
Remission Rate
+20%
Common Side Effects
Dry mouth
+25%
Constipation
+15%
Dizziness
+7%
Blurred vision
+7%
Somnolence
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov